The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Rational design of cationic lipids for siRNA delivery
Abstract
We adopted a rational approach to design cationic lipids for use in formulations to deliver small interfering RNA (siRNA). Starting with the ionizable cationic lipid 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), a key lipid component of stable nucleic acid lipid particles (SNALP) as a benchmark, we used the proposed in vivo mechanism of action of ionizable cationic lipids to guide the design of DLinDMA-based lipids with superior delivery capacity. The best-performing lipid recovered after screening (DLin-KC2-DMA) was formulated and characterized in SNALP and demonstrated to have in vivo activity at siRNA doses as low as 0.01 mg/kg in rodents and 0.1 mg/kg in nonhuman primates. To our knowledge, this represents a substantial improvement over previous reports of in vivo endogenous hepatic gene silencing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are limited published data on the in vivo delivery of self-amplifying RNA using nonviral delivery strategies (3,14,18), and none has taken advantage of the recently developed, clinically suitable delivery systems for siRNA (19,20).”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [19]
In the citing paper
“Recently, there has been an exponential growth in the development of clinically suitable nonviral delivery systems for siRNA (19,20); we have taken advantage of these innovations to develop the LNP/RNA formulation and have now embarked on a more extensive evaluation of other nonviral delivery systems.”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [19]
In the citing paper
“They can also increase the transport efficiency of siRNA by lowering toxicity and enhancing biological dispersion.319”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [319]
In the citing paper
“considerable effort has been made to reduce the siRNA payload by developing different lipid formulations for delivery, which has so far led to a tenfold or even 100-fold reduction in the dose of siRNA administered to different models77,78.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [77]
In the citing paper
“Semple et al. reported that DLin-KC2-DMA containing stable nucleic acid lipid particles (SNALPs) exhibited in vivo activity at siRNA doses of 0.01 mg/kg in the mouse model and was capable of silencing the TTR gene in nonhuman primates with ED50 around 0.3 mg/kg.[63]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [63]
Citations
Cites
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,260
Self-citationPotent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,175
Self-citationA combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
Self-citationMechanism of DNA Release from Cationic Liposome/DNA Complexes Used in Cell Transfection,
Xu, Y., & Szoka, F. C. (1996) · Biochemistry · doi:10.1021/bi9602019 · Cited by 1,136
Frank-Kamenetsky, M. D., Grefhorst, A., Anderson, N. N., Racie, T., Bramlage, B., Akinc, A., Butler, D., Charissé, K., Dorkin, J. R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 644
Self-citationMechanism of oligonucleotide release from cationic liposomes.
Zelphati, O., & Szoka, F. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11493 · Cited by 634
On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids
Hafez, I., Maurer, N., & Cullis, P. R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301506 · Cited by 601
Self-citationCationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
Heyes, J., Palmer, L., Bremner, K., & MacLachlan, I. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.014 · Cited by 572
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,003
Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer
Campani, V., Salzano, G., Lusa, S., & Rosa, G. D. (2016) · Nanomaterials · doi:10.3390/nano6070131 · Cited by 45
“DLinDMA-SNALPs The highest number of double bonds of DLinDMA reduced the phase transition temperature with a significant improvement of the transfection efficiency [66]”
BackgroundInfluentialTransfection by cationic gemini lipids and surfactants
Damen, M., Groenen, A., van Dongen, S. F. M., Nolte, R. J. M., Scholte, B. J., & Feiters, M. C. (2018) · MedChemComm · doi:10.1039/c8md00249e · Cited by 46
Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA
Raja, M. A. G., Katas, H., & Amjad, M. W. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.12.005 · Cited by 46
“[100] Semple SC , Akinc A , Chen J , et al.”
BackgroundNanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy
Zhao, G., Liu, A., Zhang, Y., Zuo, Z.-Q., Cao, Z., Zhang, H., Xu, C., & Wang, J. (2019) · Biomaterials Science · doi:10.1039/c9bm01025d · Cited by 46
Nanoparticles for local delivery of siRNA in lung therapy
Kubczak, M., Michlewska, S., Bryszewska, M. J., Aigner, A. M., & Йонов, М. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114038 · Cited by 48
Treatment of erythropoietin deficiency in mice with systemically administered siRNA
Querbes, W., Bogorad, R. L., Moslehi, J., Wong, J., Chan, A. Y., Bulgakova, E., Kuchimanchi, S., Akinc, A., Fitzgerald, K., Koteliansky, V., et al. (2012) · Blood · doi:10.1182/blood-2012-04-423715 · Cited by 45
Noncationic Material Design for Nucleic Acid Delivery
Jiang, Z., & Thayumanavan, S. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900206 · Cited by 46
Chen, Z., Yang, Y., Qiu, X., Zhou, H., Wang, R., & Xiong, H. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14500 · Cited by 46
Xu, Y., Gong, F., Golubovic, A., Strilchuk, A. W., Chen, J., Zhou, M., Dong, S., Seto, B. Y., & Li, B. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409572122 · Cited by 49
“…indicates a significant correlation between the tertiary amine - containing headgroups of ionizable lipids and their mRNA transfection potency (29); thus, the 144 LNPs were first categorized into nine groups (H1 - H9) based on the headgroup structure of their ionizable lipid for subsequent…”
Self-citationLipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases
Moosavi, S. G., Rahiman, N., Jaafari, M. R., & Arabi, L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113641 · Cited by 54
Advanced nanovehicles for cancer management
del Burgo, L. S., Pedraz, J. L., & Orive, G. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.020 · Cited by 47
Rozenfeld, J. H. K., Silva, S. D. R., Silva, P. A. R. E., Faquim-Mauro, E. L., & Carmona‐Ribeiro, A. M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.017 · Cited by 45
Toriyabe, N., Hayashi, Y., & Harashima, H. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.043 · Cited by 45
“Lipid nanoparticles such as stable nucleic acid lipid particles (SNALPs), activate the membrane-destabilizing property of a particle in the decreased pH environment in endosomes [7,8].”
BackgroundZhou, J., Wei, X., & Lei, W. (2014) · Connective Tissue Research · doi:10.3109/03008207.2014.925885 · Cited by 45
Targeted si-RNA with liposomes and exosomes (extracellular vesicles): How to unlock the potential
Antimisiaris, S. G., Mourtas, S., & Παπαδιά, Κ. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.01.056 · Cited by 46
Sato, Y., Matsui, H., Sato, R., & Harashima, H. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.06.017 · Cited by 46
Optimization of siRNA delivery to target sites: issues and future directions
Khalil, I. A., Yamada, Y., & Harashima, H. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1520836 · Cited by 48
“Ionizable or pH-sensitive lipids have been used as alternatives to cationic lipids to improve their characteristics [36,72,73].”
BackgroundTam, Y. Y. C., Chen, S., Zaifman, J., Tam, Y. K., Lin, P. J. C., Ansell, S., Roberge, M., Ciufolini, M. A., & Cullis, P. R. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.11.006 · Cited by 44
“siRNA was encapsulated in LNP using the preformed vesicle (PFV) procedure as previously described.(8) Briefly, lipids were mixed together in 30% ethanol and the mixture was slowly added to 50 mM citrate or acetate buffer, pH 4.”
BackgroundMethodInfluentialSelf-citationCationic micelle-based siRNA delivery for efficient colon cancer gene therapy
Lu, Y., Zhong, L., Jiang, Z., Pan, H., Zhang, Y., Zhu, G., Bai, L., Tong, R., Shi, J., & Duan, X. (2019) · Nanoscale Research Letters · doi:10.1186/s11671-019-2985-z · Cited by 44
RNA Therapeutics: How Far Have We Gone?
Coutinho, M. F., Matos, L., Santos, J. I., & Alves, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-19966-1_7 · Cited by 45
Fine-tuning of polyaspartamide derivatives with alicyclic moieties for systemic mRNA delivery
Yum, J., Kim, B. S., Ogura, S., Kamegawa, R., Naito, M., Yamasaki, Y., Kim, H. J., & Miyata, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.040 · Cited by 43
Glucose‐Responsive Charge‐Switchable Lipid Nanoparticles for Insulin Delivery
Liu, Y., Wang, Y., Yao, Y., Zhang, J., Liu, W., Ji, K., Wei, X., Wang, Y., Liu, X., Zhang, S., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202303097 · Cited by 43
Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders
Chu, R., Wang, Y., Kong, J., Pan, T. S., Yang, Y., & He, J. F. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02766j · Cited by 49
Transfection Potency of Lipid Nanoparticles Containing mRNA Depends on Relative Loading Levels
Liao, S., Wang, S., Wadhwa, A., Birkenshaw, A., Fox, K., Cheng, M. H. Y., Casmil, I. C., Magaña, A. A., Bathula, N. V., Ho, C.-H., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c20077 · Cited by 47
Self-citationModulation of Hepcidin as Therapy for Primary and Secondary Iron Overload Disorders
Schmidt, P. J., & Fleming, M. D. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.11.004 · Cited by 43
SPANosomes as Delivery Vehicles for Small Interfering RNA (siRNA)
Zhou, C., Mao, Y., Sugimoto, Y., Zhang, Y., Kanthamneni, N., Yu, B., Brueggemeier, R. W., Lee, L. J., & Lee, R. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200426h · Cited by 45
“AAPS J. 2010, 12, S2; Abstract T2073.”
InfluentialWalsh, C. L., Nguyen, J., & Szoka, F. C. (2012) · Chemical Communications · doi:10.1039/c2cc31710a · Cited by 43
Delivery of siRNA to the Mouse Lung via a Functionalized Lipopolyamine
Polach, K. J., Matar, M. M., Rice, J. S., Slobodkin, G., Sparks, J., Congo, R., Rea-Ramsey, A., McClure, D., Brunhoeber, E., Krampert, M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.210 · Cited by 43
Chistiakov, D. A., Sobenin, I. A., & Orekhov, A. N. (2012) · Drug Delivery · doi:10.3109/10717544.2012.738436 · Cited by 43
“By screening a library of ionizable cationic lipids with the best siRNA delivery capacity, Semple et al. (2010) developed a new lipid nanoparticle formulation to decrease an effective dose of oligonucleotides.”
BackgroundMulticomponent Synthetic Polymers with Viral-Mimetic Chemistry for Nucleic Acid Delivery
Soliman, M. E., Nasanit, R., Abulateefeh, S. R., Allen, S., Davies, M. C., Briggs, S. S., Seymour, L. W., Preece, J. A., Grabowska, A. M., Watson, S. A., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200108q · Cited by 46
Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment
Peng, Y., Bariwal, J. B., Kumar, V., Tan, C., & Mahato, R. I. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900136 · Cited by 44
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 43
“LNPs typically comprise cationic lipids that facilitate endocytosis and are released into the cytoplasm and PEGylated lipids that facilitate stabilization and prevent nonspecific interaction.(74) PEGylation also reduces immunogenicity and increases circulation time.”
Chan, C., Du, S., Dong, Y., & Cheng, X. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666201126162945 · Cited by 45
Bioinspired Lipid Nanocarriers for RNA Delivery
Golubovic, A., Tsai, S., & Li, B. (2023) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.2c00073 · Cited by 49
Tanaka, H., Hagiwara, S., Shirane, D., Yamakawa, T., Sato, Y., Matsumoto, C., Ishizaki, K., Hishinuma, M., Chida, K., Sasaki, K., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c10501 · Cited by 44
Gyanani, V., & Goswami, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041184 · Cited by 42
“precursor to the assimilation/disruption of the endosomal membrane [15].”
BackgroundTherapeutic synthetic and natural materials for immunoengineering
Slezak, A., Chang, K., Hossainy, S., Mansurov, A., Rowan, S. J., Hubbell, J. A., & Guler, M. O. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00805c · Cited by 44
Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies
Schneider, B., Grote, M., John, M., Haas, A. K., Bramlage, B., lckenstein, L. M., Jahn‐Hofmann, K., Bauss, F., Cheng, W., Croasdale, R., et al. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.39 · Cited by 42
Biodegradable nanoparticle-mediated K-ras down regulation for pancreatic cancer gene therapy
Yang, C., Hu, R., Anderson, T., Wang, Y., Lin, G., Law, W., Lin, W.-J., Nguyen, Q. T., Toh, H. T., Yoon, H. S., et al. (2015) · Journal of Materials Chemistry B · doi:10.1039/c4tb01623h · Cited by 43
Barik, S. (2010) · Viruses · doi:10.3390/v2071448 · Cited by 42
“In addition, novel second generation transfection reagents [39] and nanoparticle technology [40] are being developed to bypass the TLR pathway, which have shown promising results.”
BackgroundComprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo
Foster, D. J., Barros, S. A., Duncan, R., Shaikh, S., Cantley, W. L., Dell, A., Bulgakova, E., O′Shea, J., Taneja, N., Kuchimanchi, S., et al. (2012) · RNA · doi:10.1261/rna.031120.111 · Cited by 42
Self-citationUkawa, M., Akita, H., Hayashi, Y., Ishiba, R., Tange, K., Arai, M., Kubo, K., Higuchi, Y., Shimizu, K., Konishi, S., et al. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300629 · Cited by 45
Screening of efficient siRNA carriers in a library of surface-engineered dendrimers
Liu, H., Chang, H., Lv, J., Jiang, C., Li, Z., Wang, F., Wang, H., Wang, M., Liu, C., Wang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep25069 · Cited by 43
Development of Cationic Quaternary Ammonium Sulfonamide Amino Lipids for Nucleic Acid Delivery
Miller, J. B., Kós, P., Tieu, V., Zhou, K., & Siegwart, D. J. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b15982 · Cited by 43
Lipid-mRNA Nanoparticle Designed to Enhance Intracellular Delivery Mediated by Shock Waves
Zhang, J., Shrivastava, S., Cleveland, R. O., & Rabbitts, T. H. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b21398 · Cited by 43
Ramezanpour, M., & Tieleman, D. P. (2022) · Langmuir · doi:10.1021/acs.langmuir.2c00430 · Cited by 44
siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes
Hattori, Y., Nakamura, A., Arai, S., Kawano, K., Maitani, Y., & Yonemochi, E. (2014) · Journal of Liposome Research · doi:10.3109/08982104.2014.992024 · Cited by 42
“The effect of cationic lipid structure on siRNA transfection efficiency has been previously reported (Semple et al., 2010).”
BackgroundBolsoni, J., Liu, D. X., Mohabatpour, F., Ebner, R., Sadhnani, G., Tafech, B., Leung, J., Shanta, S. R., An, K., Morin, T., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c08644 · Cited by 45
“Encapsulating RNP at neutral pH is difficult, as MC3 (p K a 6.0 − 6.4), the ionizable cationic lipid used here, is uncharged at neutral pH. 30,43 To assess the impact of the buffer pH on the RNP activity, we varied the pH during loading and then assessed the editing efficacy.”
BackgroundInfluentialSelf-citationDesign of siRNA Therapeutics from the Molecular Scale
Angart, P. A., Vocelle, D. B., Chan, C., & Walton, S. P. (2013) · Pharmaceuticals · doi:10.3390/ph6040440 · Cited by 41
A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system
Wang, S., Wei, X., Sun, X., Chen, C., Zhou, J., Zhang, G., Wu, H., Guo, B., & Wei, L. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s142797 · Cited by 41
“20 LNP has been linked with bone formation and used for anabolic therapy, 16,21 but it has never been used in the treat-ment of cartilage diseases.”
Nanocomposites drug delivery systems for the healing of bone fractures
Chen, J., Ashames, A., Buabeid, M. A., Fahelelbom, K. M., Ijaz, M., & Murtaza, G. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119477 · Cited by 40
Self-citationLu, J., Atochina‐Vasserman, E. N., Maurya, D. S., Shalihin, M. I., Zhang, D., Chenna, S. S., Adamson, J., Liu, M., Shah, H. U. R., Shah, H., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15061572 · Cited by 40
“In 2010, Cullis laboratory developed a four-component cationic liposome for the delivery of RNA [97] that is affected by the same features as the one-component cationic liposomes.”
BackgroundXue, L., Xiong, X., Zhao, G., Arocho, W. A. M., Palanki, R., Xiao, Z., Han, X., Yoon, I., Figueroa‐Espada, C. G., Xu, J., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c10265 · Cited by 41
Self-citationNanotechnology for In vivo Targeted siRNA Delivery
Dahlman, J. E., Kauffman, K. J., Langer, R., & Anderson, D. G. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00003-1 · Cited by 41
“This conjugation significantly improved siRNA delivery compared to unmodified DLin-KC2-DMA nanoparticles in ApoE−/- mice, which could not use the endogenous ApoE-dependent endocytosis mechanism and thus forced ASGPR-mediated endocytosis.”
BackgroundMethodInfluentialSnead, N. M., & Rossi, J. J. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0361 · Cited by 40
“Their RNAi triggers maintain a 19 + 2 structure with specifically placed DNA, 2¢F, 2¢O-methyl, and phosphorothioate modifications (Akinc et al., 2008; Akinc et al., 2009; Semple et al., 2010).”
BackgroundCationic lipid nanodisks as an siRNA delivery vehicle
Ghosh, M., Ren, G., Simonsen, J. B., & Ryan, R. O. (2014) · Biochemistry and Cell Biology · doi:10.1139/bcb-2014-0027 · Cited by 40
“…(Andaloussi et al. 2011), aptamers (Li et al. 2013), antibody–protamine chimeras (Song et al. 2005; Dou et al. 2012), cationic lipids (Morrissey et al. 2005; Sørensen and Sioud 2010; Semple et al. 2010), and cationic polymers (Urban-Klein et al. 2005; Tachibana et al. 2014) as siRNA carriers.”
Biomaterials in RNAi therapeutics: quo vadis?
Wagner, E. (2013) · Biomaterials Science · doi:10.1039/c3bm60071h · Cited by 40
Self-organization of nucleic acids in lipid constructs
Kang, M., Kim, H., & Leal, C. (2016) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2016.09.006 · Cited by 42
Hadjizadeh, A., Ghasemkhah, F., & Ghasemzaie, N. (2017) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2017.1292402 · Cited by 40
“Serum proteins reduce gene transfer efficiency by neutralizing the positive charge of the complex.(75) It has been observed that gene transfer efficiency increases in low serum concentration.”
BackgroundMiller, J. B., & Siegwart, D. J. (2018) · Nano Research · doi:10.1007/s12274-018-2099-4 · Cited by 41
Microfluidics for Development of Lipid Nanoparticles: Paving the Way for Nucleic Acids to the Clinic
Ali, M. S., Hooshmand, N., El‐Sayed, M. A., & Labouta, H. I. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00732 · Cited by 40
Kulkarni, A., Deng, W., Hyun, S., & Thompson, D. H. (2012) · Bioconjugate Chemistry · doi:10.1021/bc2005158 · Cited by 39
“, hepta-6-(1′,2′diaminoethyl)-β-CD (1), hepta-6-(2′- hydroxyethylamino)-β-CD (2), and hepta-6(hydrazino)-β-CD (3).”
BackgroundMethodIonizable polymeric micelles (IPMs) for efficient siRNA delivery
Zhou, Z., Yu, F., Jiang, M., Yao, Z., Wang, J., Pan, F., Feng, R., Zhao, C., Ma, Y., Zhou, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55721-w · Cited by 42
“One hypothesis is thatthe positive charge on LNPs forms ion pairs with negatively charged intracellular lipid membranes, leading to membrane rupture and release 48 .”
Liu, L., Kim, J.-H., Li, Z., Sun, M., Trent, N., Tang, Y. J., Mcintosh, E., Karve, S., & DeRosa, F. (2025) · Nanoscale · doi:10.1039/d5nr00433k · Cited by 42
Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics
Zhao, G., Zeng, Y., Cheng, W., Karkampouna, S., Papadopoulou, P., Hu, B., Zang, S., Wezenberg, E., Forn‐Cuní, G., Lopes-Bastos, B., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c14625 · Cited by 43
A perspective on the apparent pKa of ionizable lipids in mRNA-LNPs
Simonsen, J. B., & Larsson, P. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113879 · Cited by 41
MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics
Varshney, J., & Subramanian, S. (2015) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2015.00031 · Cited by 39
“One of the studies tested this delivery method in rodents and nonhuman primates and found the siRNA delivery that targets a hepatocyte mRNA (transthyretin) was effective at dose as low as 0.01 and 0.1mg/kg, respectively (Semple et al., 2010).”
BackgroundInfluentialAkhtar, S. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.518611 · Cited by 40
“A more recent report suggests that further improvements in gene silencing activity may be obtained by a more rational approach to identifying lipid components of SNALPs [62].”
BackgroundMethodInfluentialPreclinical development of siRNA therapeutics for AL amyloidosis
Hovey, B. M., Ward, J. E., Hoo, P. S., O’Hara, C., Connors, L. H., & Seldin, D. C. (2011) · Gene Therapy · doi:10.1038/gt.2011.69 · Cited by 39
Lipid‐Modified Aminoglycoside Derivatives for In Vivo siRNA Delivery
Zhang, Y., Pelet, J. M., Heller, D. A., Dong, Y., Chen, D. L., Gu, Z., Joseph, B. J., Wallas, J., & Anderson, D. G. (2013) · Advanced Materials · doi:10.1002/adma.201301917 · Cited by 40
Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes
Singh, Y., Tomar, S., Khan, S. A., Meher, J. G., Pawar, V. K., Raval, K., Sharma, K., Singh, P. K., Chaurasia, M., Reddy, B. S., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.050 · Cited by 39
Cationic Nanohydrogel Particles for Therapeutic Oligonucleotide Delivery
Leber, N., Nuhn, L., & Zentel, R. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201700092 · Cited by 40
Self-assembled RNAi nanoflowers via rolling circle transcription for aptamer-targeted siRNA delivery
Cheng, H., Hong, S., Wang, Z., Sun, N., Wang, T., Zhang, Y., Chen, H., & Pei, R. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb00758f · Cited by 39
Yu, Q., Qiu, Y., Chen, X., Wang, X., Mei, L., Wu, H., Liu, K., Liu, Y., Li, M., Zhang, Z., et al. (2018) · Theranostics · doi:10.7150/thno.29137 · Cited by 39
“When cationic liposomes enter the blood circulation, they bond with negatively charged plasma protein in the blood, resulting in aggregation and sedimentation [18].”
BackgroundDelivery of mRNA to platelets using lipid nanoparticles
Novakowski, S. K., Jiang, K., Prakash, G., & Kastrup, C. J. (2019) · Scientific Reports · doi:10.1038/s41598-018-36910-2 · Cited by 41
Rissanou, A. N., Ouranidis, A., & Karatasos, K. (2020) · Soft Matter · doi:10.1039/d0sm00736f · Cited by 38
Ebenezer, O., Comoglio, P., Wong, G. K.-S., & Tuszynski, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044019 · Cited by 39
“DLin-KC2-DMA 2,2-dilinoleyl-4dimethylaminoethyl[1,3]-dioxola e [57]”
BackgroundInfluentialVersatile cationic lipids for siRNA delivery
Sparks, J., Slobodkin, G., Matar, M. M., Congo, R., Ulkoski, D., Rea-Ramsey, A., Pence, C., Rice, J. S., McClure, D., Polach, K. J., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.006 · Cited by 39
Development and optimization of nanosomal formulations for siRNA delivery to the liver
Kundu, A. K., Chandra, P. K., Hazari, S., Pramar, Y. V., Dash, S., & Mandal, T. K. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.10.023 · Cited by 39
“monkeys) with no obvious treatment-related changes in animal appearance or behavior [43].”
BackgroundAntonellis, P. D., Liguori, L., Falanga, A., Carotenuto, M., Ferrucci, V., Andolfo, I., Marinaro, F., Scognamiglio, I., Virgilio, A., Rosa, G. D., et al. (2013) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-013-0837-4 · Cited by 39
“SNALPs can be considered as an evolution of these cationic liposomes that can encapsulate nucleic acids into their internal aqueous cavity and thus stabilize them in biological fluids (Semple et al. 2010).”
BackgroundProduction and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases
Vadovics, M., Muramatsu, H., Sárközy, A., & Pardi, N. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_7 · Cited by 40
Wu, K., Xu, F., Dai, Y., Jin, S., Zheng, A., Zhang, N., & Xu, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.007 · Cited by 37
Rational design of lipid nanoparticles for enabling gene therapies
Brimacombe, C. A., Kulkarni, J. A., Cheng, M. H. Y., An, K., Witzigmann, D., & Cullis, P. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101518 · Cited by 45
“127 The related preformed vesicle formulation process 121 that was used to develop the optimized lipids DLinKC2DMA 23 and DLinMC3DMA 129 consisted of ionizable lipid/DSPC/cholesterol/ PEG-lipid (40/10/40/10 mol”
InfluentialSelf-citationNanotechnology for immuno-oncology
Grippin, A., Lee, D., Parkes, E. E., Jiang, W., & Kim, B. Y. S. (2025) · Nature Cancer · doi:10.1038/s43018-025-01025-x · Cited by 48
Next Generation Delivery System for Proteins and Genes of Therapeutic Purpose: Why and How?
Sharma, A. R., Kundu, S. K., Nam, J., Sharma, G., Doss, C. G. P., Lee, S., & Chakraborty, C. (2014) · BioMed Research International · doi:10.1155/2014/327950 · Cited by 41
Hean, J., Crowther, C. E., Ely, A., Islam, R. U., Barichievy, S., Bloom, K. M., Weinberg, M. S., van Otterlo, W. A. L., de Koning, C. B., Salazar, F. H., et al. (2010) · Artificial DNA PNA & XNA · doi:10.4161/adna.1.1.11981 · Cited by 39
Xu, Y., Ou, M., Keough, E., Roberts, J., Koeplinger, K., Lyman, M., Fauty, S. E., Carlini, E., Stern, M., Zhang, R., et al. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400584h · Cited by 38
Ojeda, E., Puras, G., Agirre, M., Sesma, J. Z., Grijalvo, S., Eritja, R., Digiacomo, L., Caracciolo, G., & Pedraz, J. L. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.02.043 · Cited by 38
“Additionally, squalene has shown to increase the phagocytic activity of cells due to its capacity to potentiate the immune response in a nontoxic manner (Allison and Byars, 1986; Seubert et al., 2008).”
BackgroundReddy, L. H., & Bazile, D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.08.012 · Cited by 39
Wang, C., Du, L., Zhou, J., Meng, L., Cheng, Q., Wang, C., Wang, X., Zhao, D., Huang, Y., Zheng, S., et al. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b07337 · Cited by 38
Self-Assembled DNA Nanostructures-Based Nanocarriers Enabled Functional Nucleic Acids Delivery
Huang, J. L., Ma, W., Sun, H., Wang, H., He, X., Cheng, H., Huang, M., Lei, Y., & Wang, K. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b01197 · Cited by 38
Yamada, Y., Sato, Y., Nakamura, T., & Harashima, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.007 · Cited by 41
Acidic pH-induced changes in lipid nanoparticle membrane packing
Koitabashi, K., Nagumo, H., Nakao, M., Machida, T., Yoshida, K., & Sakai‐Kato, K. (2021) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2021.183627 · Cited by 40
Novel Ionizable Lipid Nanoparticles for SARS‐CoV‐2 Omicron mRNA Delivery
Long, J., Yu, C., Zhang, H., Cao, Y., Sang, Y., Lü, H., Zhang, Z., Wang, X., Wang, H., Song, G., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202590 · Cited by 36
Yan, J., Zhang, H., Li, G., Su, J., Wei, Y., & Xu, C. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.10.012 · Cited by 40
“5E 57,58,93 e 95 .”
BackgroundMethodInfluentialSilicon Ether Ionizable Lipids Enable Potent mRNA Lipid Nanoparticles with Rapid Tissue Clearance
Holland, R., Lam, K., Jeng, S. C. Y., McClintock, K., Palmer, L., Schreiner, P., Wood, M., Zhao, W., & Heyes, J. A. (2024) · ACS Nano · doi:10.1021/acsnano.3c09028 · Cited by 38
Self-citationCationic α-Cyclodextrin:Poly(ethylene glycol) Polyrotaxanes for siRNA Delivery
Kulkarni, A., DeFrees, K., Schuldt, R. A., Hyun, S., Wright, K. J., Yerneni, C. K., VerHeul, R., & Thompson, D. H. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300449t · Cited by 37
Membrane Permeabilization Induced by Sphingosine: Effect of Negatively Charged Lipids
Jiménez‐Rojo, N., Sot, J., Viguera, A. R., Collado, M. I., Torrecillas, A., Gómez-Fernández, J. C., Goñi, F. M., & Alonso, A. (2014) · Biophysical Journal · doi:10.1016/j.bpj.2014.04.038 · Cited by 37
“It has been reported (7) that upon interaction between a cationic and an anionic lipid in the endosomal membrane, non-lamellar structures can be formed, which could in turn disrupt the membrane.”
BackgroundAmyloid heart disease: genetics translated into disease-modifying therapy
Sperry, B. W., & Tang, W. H. W. (2017) · Heart · doi:10.1136/heartjnl-2016-309914 · Cited by 39
Drug delivery across length scales
Delcassian, D., Patel, A. K., Cortinas, A. B., & Langer, R. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1438440 · Cited by 39
“Similarly, lipid nanoparticles carrying nucleic acids were shown to accumulate in the liver after adsorption of apolipoprotein E [189,190].”
Background
Metadata
- Authors
- Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., Hafez, I. M., Dorkin, J. R., Qin, J., Lam, K., Rajeev, K. G., Wong, K. F., Jeffs, L. B., Nechev, L., Eisenhardt, M. L., Jayaraman, M., Kazem, M., Maier, M. A., Srinivasulu, M., Weinstein, M. J., Chen, Q., Alvarez, R., Barros, S. A., De, S., Klimuk, S. K., Borland, T., Kosovrasti, V., Cantley, W. L., Tam, Y. K., Manoharan, M., Ciufolini, M. A., Tracy, M. A., de Fougerolles, A., MacLachlan, I., Cullis, P. R., Madden, T. D., & Hope, M. J.
- Affiliations
- Arbutus Biopharma (Canada) (CA)
- Alnylam Pharmaceuticals (United States) (US)
- University of British Columbia (CA)
- Corresponding author
- Semple, Sean C
- Akinc, Akin
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2010-01-17
- Volume
- 28
- Issue
- 2
- Pages
- 172-176
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2083249633
- Cited by
- 1,822
- References
- 24
- Citations by year
- 2026: 124 · 2025: 165 · 2024: 175 · 2023: 145 · 2022: 145 · 2021: 119 · 2020: 90 · 2019: 102 · 2018: 83 · 2017: 85 · 2016: 95 · 2015: 85 · 2014: 105 · 2013: 103 · 2012: 98
- FWCI
- 39.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alnylam Pharmaceuticals
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- siRNA delivery, lipid nanoparticles, RNAi therapeutics, ionizable cationic lipids
- MeSH terms
- Cations, Drug Carriers, Drug Compounding, Lipids, Transfection, Drug Design, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
